(Q37352035)

19 August 2017

title

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence (English)

1 reference

major depressive disorder

19 August 2017

main subject

1 reference

Jayesh Kamath

1

1 reference

19 August 2017

Venkatesh Handratta

series ordinal

2

1 reference

19 August 2017

language of work or name

1 reference

1 December 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

1787-1797

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Recovery, chronicity, and levels of psychopathology in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Mood disorders in the medically ill: scientific review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Clinical and health services relationships between major depression, depressive symptoms, and general medical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Report by the ACNP Task Force on response and remission in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Why do we need new and better antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Venlafaxine for the control of hot flashes: results of a longitudinal continuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1787

10.1586/14737175.8.12.1787

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference